Literature DB >> 14659079

Nomega-nitro-L-arginine methylester ameliorates myocardial toxicity induced by doxorubicin.

Mahmoud Ahmed Mansour1, Ayman Gamal El-Din, Mahmoud N Nagi, Othman A Al-Shabanah, Abdullah M Al-Bekairi.   

Abstract

The effects of Nomega-nitro-L-arginine methylester (L-NAME) and L-arginine on cardiotoxicity that is induced by doxorubicin (Dox) were investigated. A single dose of Dox 15 mg/kg i.p. induced cardiotoxicity, manifested biochemically by a significant elevation of serum creatine phosphokinase (CPK) activity [EC 2.7.3.2]. Moreover, cardiotoxicity was further confirmed by a significant increase in lipid peroxides, measured as malon-di-aldehyde (MDA) in cardiac tissue homogenates. The administration of L-NAME 4 mg/kg/d p.o. in drinking water 5 days before and 3 days after the Dox injection significantly ameliorated the cardiotoxic effects of Dox, judged by the improvement in both serum CPK activity and lipid peroxides in the cardiac tissue homogenates. On the other hand, the administration of L-arginine 70 mg/kg/d p.o. did not protect the cardiac tissues against the toxicity that was induced by the Dox treatment. The findings of this study suggest that L-NAME can attenuate the cardiac dysfunction that is produced by the Dox treatment via the mechanism(s), which may involve the inhibition of the nitric oxide (NO) formation. L-NAME may, therefore, be a beneficial remedy for cardiotoxicity that is induced by Dox and can then be used to improve the therapeutic index of Dox.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659079     DOI: 10.5483/bmbrep.2003.36.6.593

Source DB:  PubMed          Journal:  J Biochem Mol Biol        ISSN: 1225-8687


  5 in total

1.  The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin.

Authors:  Agnieszka Korga; Jaroslaw Dudka; Franciszek Burdan; Justyna Sliwinska; Slawomir Mandziuk; Katarzyna Dawidek-Pietryka
Journal:  Oxid Med Cell Longev       Date:  2012-02-26       Impact factor: 6.543

2.  Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca²⁺ balance protein levels.

Authors:  Justyna Sliwinska; Jaroslaw Dudka; Agnieszka Korga; Franciszek Burdan; Wlodzimierz Matysiak; Barbara Jodlowska-Jedrych; Slawomir Mandziuk; Katarzyna Dawidek-Pietryka
Journal:  Oxid Med Cell Longev       Date:  2012-05-15       Impact factor: 6.543

3.  Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.

Authors:  Yang QuanJun; Yang GenJin; Wan LiLi; Han YongLong; Huo Yan; Li Jie; Huang JinLu; Lu Jin; Gan Run; Guo Cheng
Journal:  PLoS One       Date:  2017-01-10       Impact factor: 3.240

4.  Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase.

Authors:  Jaroslaw Dudka; Franciszek Burdan; Agnieszka Korga; Magdalena Iwan; Barbara Madej-Czerwonka; Monika Cendrowska-Pinkosz; Agnieszka Korobowicz-Markiewicz; Barbara Jodlowska-Jedrych; Wlodzimierz Matysiak
Journal:  Oxid Med Cell Longev       Date:  2012-08-23       Impact factor: 6.543

5.  Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity.

Authors:  Jaroslaw Dudka; Renata Gieroba; Agnieszka Korga; Franciszek Burdan; Wlodzimierz Matysiak; Barbara Jodlowska-Jedrych; Slawomir Mandziuk; Elzbieta Korobowicz; Marek Murias
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-26       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.